Sutro Biopharma Inc STRO
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-09-27 |
| Shares Out. | 16,570,000 |
| Website | sutrobio.com/ ↗ |
| Phone | 13026587581 |
| Employees | 128 |
| Revenue | $9.8M |
| Gross Profit | $9.8M |
| Net Income | -$38.5M |
| Free Cash Flow | -$145.6M |
| Total Assets | $194.5M |
| Total Liabilities | $297.8M |
| Equity | -$103.3M |
About Sutro Biopharma Inc
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Sutro Biopharma Inc is a publicly traded company under the ticker symbol STRO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-09-01)